Depatuxizumab - CAS 1471999-69-5

Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN) .

EGFR

Angiogenesis, Tyrosine Kinase/Adaptors, JAK/STAT signaling

1471925

0.993

-20°C

Ice Packs

Inhibitory Antibodies